Kintara Pharma (KTRA) Price to Earnings Ratio

Kintara Therapeutics Inc - graphic logo of issuer KTRA

This price chart for Kintara Therapeutics (KTRA), now HURA, reflects a value of -3.00. The company's growth relies on the implementation of IFx-Hu2.0 personalized cancer vaccines and the fight against tumor resistance. The merger with TuHURA led to a complete shift in the scientific development vector toward breakthrough tests. However, the business remains vulnerable due to a funding shortage and a critical dependence on the success of VAL-083 trials.

Kintara (KTRA) - Price to Earnings Ratio from 07/04/2022 to 11/16/2026

Comprehensive metric breakdowns and analytics for kintara.com (KTRA)

Comprehensive company analysis:KTRA (Kintara Therapeutics Inc)
Product sample of Kintara Therapeutics

The P/E ratio reflects the relationship between a stock's market value and its net income, measuring the investment payback period. Investors evaluate this coefficient to determine asset overbought conditions and the sustainability of a long-term trend. Analyzing the current market P/E of a company can reveal hidden risks or capital undervaluation. For Kintara Therapeutics (KTRA), this metric is critical due to the low cost of drug synthesis. Successful scalability of brain cancer treatment formulas could radically alter this indicator.